Advanced
  Home Compare Reports

Comparison with Similar Reports

Hemostats Market by Type (Thrombin, Oxidised Regenerated Cellulose, Combination, Gelatin, Collagen), Application (Orthopedic Surgery, General Surgery,...

Publisher:        MarketsandMarkets

# of Pages:        224

Rating: 

1 User License $4,950

Publication Date:  July, 2021

Price:       $4,950 / User License




1 INTRODUCTION 27
1.1 OBJECTIVES OF THE STUDY 27
1.2 MARKET DEFINITION 27
1.2.1 INCLUSIONS AND EXCLUSIONS OF THE STUDY 28
1.3 MARKET SCOPE 29
1.3.1 MARKETS COVERED 29
1.3.2 YEARS CONSIDERED FOR THE STUDY 30
1.4 CURRENCY 30
TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD 30
1.5 LIMITATIONS 31
1.6 STAKEHOLDERS 31
1.7 SUMMARY OF CHANGES 31
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
FIGURE 1 RESEARCH DESIGN 33
2.1.1 SECONDARY DATA 34
2.1.1.1 Secondary sources 35
2.1.2 PRIMARY DATA 35
FIGURE 2 PRIMARY SOURCES 36
2.1.2.1 Key data from primary sources 37
2.1.2.2 Key industry insights 38
2.1.2.3 Breakdown of primary interviews: By company type, designation,
and region 38
2.2 MARKET SIZE ESTIMATION 39
FIGURE 3 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 39
FIGURE 4 REVENUE SHARE ANALYSIS ILLUSTRATION—BAXTER INTERNATIONAL, INC. 40
FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 41
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 42
FIGURE 7 TOP-DOWN APPROACH 42
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 44
FIGURE 8 DATA TRIANGULATION METHODOLOGY 44
2.4 MARKET SHARE ANALYSIS 44
2.5 ASSUMPTIONS FOR THE STUDY 45
2.6 LIMITATIONS 45
2.6.1 METHODOLOGY-RELATED LIMITATIONS 45
2.7 RISK ASSESSMENT 46
TABLE 2 RISK ASSESSMENT: HEMOSTATS MARKET 46
2.8 COVID-19 HEALTH ASSESSMENT 46
2.9 COVID-19 ECONOMIC ASSESSMENT 46
2.10 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 47
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY 47
FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 48
3 EXECUTIVE SUMMARY 49
FIGURE 11 HEMOSTATS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION) 49
FIGURE 12 HEMOSTATS MARKET, BY FORMULATION, 2021 VS. 2026 (USD MILLION) 50
FIGURE 13 HEMOSTATS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION) 50
FIGURE 14 HEMOSTATS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION) 51
4 PREMIUM INSIGHTS 52
4.1 HEMOSTATS MARKET OVERVIEW 52
FIGURE 15 NEED TO MANAGE BLOOD LOSS IN PATIENTS DURING SURGICAL PROCEDURES TO DRIVE MARKET GROWTH 52
4.2 ASIA PACIFIC: HEMOSTATS MARKET, BY FORMULATION & COUNTRY (2020) 53
FIGURE 16 MATRIX & GEL HEMOSTATS SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2020 53
4.3 HEMOSTATS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 54
FIGURE 17 INDIA TO REGISTER THE HIGHEST REVENUE GROWTH DURING THE FORECAST PERIOD 54
4.4 HEMOSTATS MARKET, BY TYPE (2021–2026) 55
FIGURE 18 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS WILL CONTINUE TO DOMINATE THE HEMOSTATS MARKET DURING THE FORECAST PERIOD 55
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
5.2 MARKET DYNAMICS 56
FIGURE 19 HEMOSTATS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56
5.2.1 DRIVERS 57
5.2.1.1 Growing volume of surgical procedures performed 57
TABLE 3 UK: NUMBER OF CARDIAC SURGICAL PROCEDURES, 2010-2019 57
5.2.1.2 Rising focus on R&D 57
5.2.1.3 Increasing incidence of sports-related injuries and spinal ailments 58
5.2.1.4 Rising focus on effective blood loss management in patients during surgeries 58
5.2.2 OPPORTUNITIES 59
5.2.2.1 Growth in the number of hospitals & surgical centers 59
5.2.2.2 Growing adoption of advanced hemostats in emerging markets 59
TABLE 4 COST OF SURGICAL PROCEDURES: US VS. INDIA (USD) 60
5.2.3 RESTRAINTS 60
5.2.3.1 Side effects and allergic reactions associated with hemostats 60
5.2.3.2 Highly consolidated market 61
5.2.4 CHALLENGES 61
5.2.4.1 Dearth of skilled personnel for the effective use of hemostats 61
5.2.4.2 Stringent regulatory framework 61
5.2.4.3 High cost of hemostats 62
5.3 COVID-19 IMPACT ANALYSIS 62
5.4 RANGES/SCENARIOS 63
FIGURE 20 PESSIMISTIC SCENARIO 63
FIGURE 21 OPTIMISTIC SCENARIO 64
FIGURE 22 REALISTIC SCENARIO 64
5.5 REGULATORY ANALYSIS 65
TABLE 5 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING HEMOSTATS 65
5.5.1 NORTH AMERICA 66
5.5.1.1 US 66
TABLE 6 CLASSIFICATION OF MEDICAL DEVICES BY THE US FDA 66
FIGURE 23 PREMARKET NOTIFICATION: 510(K) APPROVAL FOR MEDICAL DEVICES 67
5.5.1.2 Canada 67
FIGURE 24 APPROVAL PROCESS FOR CLASS III MEDICAL DEVICES IN CANADA 67
5.5.2 EUROPE 68
FIGURE 25 CE APPROVAL PROCESS IN EUROPE FOR HEMOSTATS 68
5.5.3 ASIA PACIFIC 68
5.5.3.1 Japan 68
TABLE 7 CLASSIFICATION OF MEDICAL DEVICES AND THE REVIEWING BODY IN JAPAN 69
5.5.3.2 China 69
TABLE 8 NMPA MEDICAL DEVICES CLASSIFICATION 69
5.5.3.3 India 70
TABLE 9 CLASSIFICATION OF HEMOSTATS IN INDIA 70
5.6 PORTER’S FIVE FORCES ANALYSIS 70
TABLE 10 PORTER’S FIVE FORCES ANALYSIS 70
5.6.1 THREAT OF NEW ENTRANTS 70
5.6.2 THREAT OF SUBSTITUTES 71
5.6.3 BARGAINING POWER OF SUPPLIERS 71
5.6.4 BARGAINING POWER OF BUYERS 71
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 71
5.7 TECHNOLOGY ANALYSIS 72
5.8 VALUE CHAIN ANALYSIS 72
FIGURE 26 VALUE CHAIN ANALYSIS: MAXIMUM VALUE IS ADDED DURING
THE MANUFACTURING PHASE 73
5.9 SUPPLY CHAIN ANALYSIS 73
FIGURE 27 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES 74
5.10 PATENT ANALYSIS 74
5.10.1 PATENT GRANTED TRENDS FOR HEMOSTATS 74
FIGURE 28 PATENT GRANTED TRENDS, JANUARY 2011–JULY 2021 75
5.10.2 JURISDICTION AND TOP APPLICANT ANALYSIS 75
FIGURE 29 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR HEMOSTAT PATENTS, JANUARY 2011 TO JULY 2021 75
5.10.3 PUBLICATION TRENDS FOR HEMOSTATS 76
5.11 TRADE ANALYSIS 76
5.11.1 TRADE ANALYSIS FOR HEMOSTATS 76
TABLE 11 IMPORT DATA FOR HEMOSTATS, BY COUNTRY, 2016–2020 (USD MILLION) 76
TABLE 12 EXPORT DATA FOR HEMOSTATS, BY COUNTRY, 2016–2020 (USD MILLION) 77
5.12 PRICING ANALYSIS 77
TABLE 13 AVERAGE SELLING PRICE FOR HEMOSTATS 77
5.13 ECOSYSTEM ANALYSIS 78
FIGURE 30 HEMOSTATS MARKET: ECOSYSTEM ANALYSIS 78
5.13.1 ROLE IN THE ECOSYSTEM 78
FIGURE 31 KEY PLAYERS 79
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 80
5.14.1 REVENUE SHIFT & REVENUE POCKETS FOR HEMOSTAT MANUFACTURERS 80
6 HEMOSTATS MARKET, BY TYPE 81
6.1 INTRODUCTION 82
TABLE 14 HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 82
TABLE 15 HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 82
6.2 THROMBIN-BASED HEMOSTATS 83
6.2.1 DEVELOPMENTS IN RECOMBINANT THROMBIN PRODUCTS TO SUPPORT
THE GROWTH OF THIS MARKET 83
TABLE 16 MAJOR PRODUCTS IN THE THROMBIN-BASED HEMOSTATS MARKET 83
TABLE 17 THROMBIN-BASED HEMOSTATS MARKET, BY REGION,
2016–2019 (USD MILLION) 84
TABLE 18 THROMBIN-BASED HEMOSTATS MARKET, BY REGION,
2020–2026 (USD MILLION) 84
6.3 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS 84
6.3.1 VENDORS ARE EXPANDING THE AVAILABILITY OF THEIR ORC-BASED HEMOSTATIC AGENTS ACROSS UNTAPPED MARKETS IN THE APAC 84
TABLE 19 MAJOR PRODUCTS IN THE OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET 85
TABLE 20 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET,
BY REGION, 2016–2019 (USD MILLION) 85
TABLE 21 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET,
BY REGION, 2020–2026 (USD MILLION) 86
6.4 COMBINATION HEMOSTATS 86
6.4.1 ADVANCEMENTS IN COMBINATION MATERIALS ARE SUPPORTING
THE GROWTH OF THIS SEGMENT 86
TABLE 22 MAJOR PRODUCTS IN THE COMBINATION HEMOSTATS MARKET 86
TABLE 23 COMBINATION HEMOSTATS MARKET, BY REGION,
2016–2019 (USD MILLION) 87
TABLE 24 COMBINATION HEMOSTATS MARKET, BY REGION,
2020–2026 (USD MILLION) 87
6.5 GELATIN-BASED HEMOSTATS 87
6.5.1 GELATIN-BASED HEMOSTATS OFFER HIGH ELASTICITY 87
TABLE 25 MAJOR PRODUCTS IN THE GELATIN-BASED HEMOSTATS MARKET 88
TABLE 26 GELATIN-BASED HEMOSTATS MARKET, BY REGION,
2016–2019 (USD MILLION) 88
TABLE 27 GELATIN-BASED HEMOSTATS MARKET, BY REGION,
2020–2026 (USD MILLION) 88
6.6 COLLAGEN-BASED HEMOSTATS 89
6.6.1 LOW COST AND REDUCED RISK OF DISEASE TRANSMISSION ARE PROMOTING THE ADOPTION OF COLLAGEN-BASED HEMOSTATS 89
TABLE 28 MAJOR PRODUCTS IN THE COLLAGEN-BASED HEMOSTATS MARKET 89
TABLE 29 COLLAGEN-BASED HEMOSTATS MARKET, BY REGION,
2016–2019 (USD MILLION) 90
TABLE 30 COLLAGEN-BASED HEMOSTATS MARKET, BY REGION,
2020–2026 (USD MILLION) 90
7 HEMOSTATS MARKET, BY FORMULATION 91
7.1 INTRODUCTION 92
TABLE 31 HEMOSTATS MARKET, BY FORMULATION, 2016–2019 (USD MILLION) 92
TABLE 32 HEMOSTATS MARKET, BY FORMULATION, 2020–2026 (USD MILLION) 92
7.2 MATRIX & GEL HEMOSTATS 92
7.2.1 MATRIX & GEL HEMOSTATS ENHANCE PLATELET AGGREGATION 92
TABLE 33 MATRIX & GEL HEMOSTATS MARKET, BY REGION,
2016–2019 (USD MILLION) 93
TABLE 34 MATRIX & GEL HEMOSTATS MARKET, BY REGION,
2020–2026 (USD MILLION) 93
7.3 SHEET & PAD HEMOSTATS 93
7.3.1 SHEET & PAD HEMOSTATS CAN BE CUT INTO ANY SHAPE OR SIZE, DEPENDING ON THE SURGICAL WOUND 93
TABLE 35 SHEET & PAD HEMOSTATS MARKET, BY REGION, 2016–2019 (USD MILLION) 94
TABLE 36 SHEET & PAD HEMOSTATS MARKET, BY REGION, 2020–2026 (USD MILLION) 94
7.4 SPONGE HEMOSTATS 94
7.4.1 SPONGE HEMOSTATS TO WITNESS THE HIGHEST GROWTH DURING
THE FORECAST PERIOD 94
TABLE 37 SPONGE HEMOSTATS MARKET, BY REGION, 2016–2019 (USD MILLION) 95
TABLE 38 SPONGE HEMOSTATS MARKET, BY REGION, 2020–2026 (USD MILLION) 95
7.5 POWDER HEMOSTATS 95
7.5.1 POWDER FORMULATIONS CAN BE SPRAYED DIRECTLY ON THE WOUND 95
TABLE 39 POWDER HEMOSTATS MARKET, BY REGION, 2016–2019 (USD MILLION) 96
TABLE 40 POWDER HEMOSTATS MARKET, BY REGION, 2020–2026 (USD MILLION) 96
 
8 HEMOSTATS MARKET, BY APPLICATION 97
8.1 INTRODUCTION 98
TABLE 41 HEMOSTATS MARKET, BY APPLICATION, 2016–2019 (USD MILLION) 98
TABLE 42 HEMOSTATS MARKET, BY APPLICATION, 2020–2026 (USD MILLION) 98
8.2 ORTHOPEDIC SURGERY 99
8.2.1 ORTHOPEDIC SURGERY IS THE LARGEST APPLICATION SEGMENT FOR HEMOSTATS 99
TABLE 43 HEMOSTATS MARKET FOR ORTHOPEDIC SURGERY, BY REGION,
2016–2019 (USD MILLION) 100
TABLE 44 HEMOSTATS MARKET FOR ORTHOPEDIC SURGERY, BY REGION,
2020–2026 (USD MILLION) 100
8.3 GENERAL SURGERY 100
8.3.1 INCREASING NUMBER OF HERNIA REPAIR PROCEDURES TO DRIVE
THE GROWTH OF THIS SEGMENT 100
TABLE 45 HEMOSTATS MARKET FOR GENERAL SURGERY, BY REGION,
2016–2019 (USD MILLION) 101
TABLE 46 HEMOSTATS MARKET FOR GENERAL SURGERY, BY REGION,
2020–2026 (USD MILLION) 101
8.4 NEUROLOGICAL SURGERY 102
8.4.1 GROWING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH 102
TABLE 47 HEMOSTATS MARKET FOR NEUROLOGICAL SURGERY, BY REGION,
2016–2019 (USD MILLION) 102
TABLE 48 HEMOSTATS MARKET FOR NEUROLOGICAL SURGERY, BY REGION,
2020–2026 (USD MILLION) 103
8.5 CARDIOVASCULAR SURGERY 103
8.5.1 RISING PREVALENCE OF CVD TO DRIVE THE ADOPTION OF HEMOSTATS 103
TABLE 49 HEMOSTATS MARKET FOR CARDIOVASCULAR SURGERY, BY REGION,
2016–2019 (USD MILLION) 104
TABLE 50 HEMOSTATS MARKET FOR CARDIOVASCULAR SURGERY, BY REGION,
2020–2026 (USD MILLION) 104
8.6 RECONSTRUCTIVE SURGERY 104
8.6.1 GROWING NUMBER OF FACIAL COSMETIC SURGERIES TO SUPPORT MARKET GROWTH 104
TABLE 51 HEMOSTATS MARKET FOR RECONSTRUCTIVE SURGERY, BY REGION,
2016–2019 (USD MILLION) 105
TABLE 52 HEMOSTATS MARKET FOR RECONSTRUCTIVE SURGERY, BY REGION,
2020–2026 (USD MILLION) 105
8.7 GYNECOLOGICAL SURGERY 106
8.7.1 HEMOSTATS ARE COMMONLY USED IN C-SECTION PROCEDURES TO CONTROL SURGICAL BLEEDING AND RELATED COMPLICATIONS 106
TABLE 53 C-SECTION SURGERIES PER 1,000 BIRTHS (2018) 106
TABLE 54 HEMOSTATS MARKET FOR GYNECOLOGICAL SURGERY, BY REGION,
2016–2019 (USD MILLION) 107
TABLE 55 HEMOSTATS MARKET FOR GYNECOLOGICAL SURGERY, BY REGION,
2020–2026 (USD MILLION) 107
8.8 OTHER SURGERIES 107
TABLE 56 HEMOSTATS MARKET FOR OTHER SURGERIES, BY REGION,
2016–2019 (USD MILLION) 108
TABLE 57 HEMOSTATS MARKET FOR OTHER SURGERIES, BY REGION,
2020–2026 (USD MILLION) 108
9 HEMOSTATS MARKET, BY REGION 109
9.1 INTRODUCTION 110
TABLE 58 HEMOSTATS MARKET, BY REGION, 2016–2019 (USD MILLION) 110
TABLE 59 HEMOSTATS MARKET, BY REGION, 2020–2026 (USD MILLION) 110
9.2 NORTH AMERICA 111
FIGURE 32 NORTH AMERICA: HEMOSTATS MARKET SNAPSHOT 112
TABLE 60 NORTH AMERICA: HEMOSTATS MARKET, BY COUNTRY,
2016–2019 (USD MILLION) 113
TABLE 61 NORTH AMERICA: HEMOSTATS MARKET, BY COUNTRY,
2020–2026 (USD MILLION) 113
TABLE 62 NORTH AMERICA: HEMOSTATS MARKET, BY TYPE,
2016–2019 (USD MILLION) 113
TABLE 63 NORTH AMERICA: HEMOSTATS MARKET, BY TYPE,
2020–2026 (USD MILLION) 114
TABLE 64 NORTH AMERICA: HEMOSTATS MARKET, BY FORMULATION,
2016–2019 (USD MILLION) 114
TABLE 65 NORTH AMERICA: HEMOSTATS MARKET, BY FORMULATION,
2020–2026 (USD MILLION) 114
TABLE 66 NORTH AMERICA: HEMOSTATS MARKET, BY APPLICATION,
2016–2019 (USD MILLION) 115
TABLE 67 NORTH AMERICA: HEMOSTATS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 115
9.2.1 US 115
9.2.1.1 The US dominates the North American hemostats market 115
TABLE 68 US: KEY MACROINDICATORS 117
TABLE 69 US: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 117
TABLE 70 US: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 117
9.2.2 CANADA 118
9.2.2.1 Growing geriatric population and the increasing volume of surgeries to drive the demand for hemostats in Canada 118
TABLE 71 SURGICAL PROCEDURES PERFORMED IN CANADA, 2019 118
TABLE 72 CANADA: KEY MACROINDICATORS 119
TABLE 73 CANADA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 119
TABLE 74 CANADA: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 119
9.3 EUROPE 120
TABLE 75 EUROPE: HEMOSTATS MARKET, BY COUNTRY, 2016–2019 (USD MILLION) 120
TABLE 76 EUROPE: HEMOSTATS MARKET, BY COUNTRY, 2020–2026 (USD MILLION) 121
TABLE 77 EUROPE: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 121
TABLE 78 EUROPE: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 122
TABLE 79 EUROPE: HEMOSTATS MARKET, BY FORMULATION,
2016–2019 (USD MILLION) 122
TABLE 80 EUROPE: HEMOSTATS MARKET, BY FORMULATION,
2020–2026 (USD MILLION) 122
TABLE 81 EUROPE: HEMOSTATS MARKET, BY APPLICATION,
2016–2019 (USD MILLION) 123
TABLE 82 EUROPE: HEMOSTATS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 123
9.3.1 GERMANY 123
9.3.1.1 High healthcare expenditure in Germany to favor market growth 123
TABLE 83 SURGICAL PROCEDURES PERFORMED IN GERMANY, 2019 124
TABLE 84 GERMANY: KEY MACROINDICATORS 124
TABLE 85 GERMANY: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 125
TABLE 86 GERMANY: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 125
9.3.2 UK 125
9.3.2.1 Growing volume of hernia repair and cardiovascular surgeries in
the UK to drive market growth 125
TABLE 87 SURGICAL PROCEDURES PERFORMED IN THE UK, 2019 126
TABLE 88 UK: KEY MACROINDICATORS 126
TABLE 89 UK: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 127
TABLE 90 UK: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 127
9.3.3 FRANCE 127
9.3.3.1 Presence of a well-established healthcare system and growing geriatric population to propel market growth 127
TABLE 91 SURGICAL PROCEDURES PERFORMED IN FRANCE, 2019 128
TABLE 92 FRANCE: KEY MACROINDICATORS 128
TABLE 93 FRANCE: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 129
TABLE 94 FRANCE: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 129
9.3.4 ITALY 129
9.3.4.1 Increasing volume of surgeries to drive the demand for hemostats in the country 129
TABLE 95 SURGICAL PROCEDURES PERFORMED IN ITALY, 2019 130
TABLE 96 ITALY: KEY MACROINDICATORS 130
TABLE 97 ITALY: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 131
TABLE 98 ITALY: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 131
9.3.5 SPAIN 131
9.3.5.1 Growing healthcare budget and rising efforts for boosting the local manufacturing of medical products to drive market growth 131
TABLE 99 SURGICAL PROCEDURES PERFORMED IN SPAIN, 2019 132
TABLE 100 SPAIN: KEY MACROINDICATORS 132
TABLE 101 SPAIN: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 133
TABLE 102 SPAIN: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 133
9.3.6 RUSSIA 133
9.3.6.1 Rising public healthcare expenditure to support market growth 133
TABLE 103 RUSSIA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 134
TABLE 104 RUSSIA: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 134
9.3.7 SWITZERLAND 134
9.3.7.1 Increasing public health insurance coverage to drive the number of surgical procedures 134
TABLE 105 SURGICAL PROCEDURES PERFORMED IN SWITZERLAND, 2019 135
TABLE 106 SWITZERLAND: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 135
TABLE 107 SWITZERLAND: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 136
9.3.8 BELGIUM 136
9.3.8.1 Increasing demand for value-based healthcare services to drive market growth 136
TABLE 108 SURGICAL PROCEDURES PERFORMED IN BELGIUM, 2019 136
TABLE 109 BELGIUM: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 137
TABLE 110 BELGIUM: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 137
9.3.9 REST OF EUROPE 137
TABLE 111 ROE: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 138
TABLE 112 ROE: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 138
9.4 ASIA PACIFIC 138
FIGURE 33 APAC: HEMOSTATS MARKET SNAPSHOT 139
TABLE 113 ASIA PACIFIC: HEMOSTATS MARKET, BY COUNTRY,
2016–2019 (USD MILLION) 140
TABLE 114 ASIA PACIFIC: HEMOSTATS MARKET, BY COUNTRY,
2020–2026 (USD MILLION) 140
TABLE 115 ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 141
TABLE 116 ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 141
TABLE 117 ASIA PACIFIC: HEMOSTATS MARKET, BY FORMULATION,
2016–2019 (USD MILLION) 141
TABLE 118 ASIA PACIFIC: HEMOSTATS MARKET, BY FORMULATION,
2020–2026 (USD MILLION) 142
TABLE 119 ASIA PACIFIC: HEMOSTATS MARKET, BY APPLICATION,
2016–2019 (USD MILLION) 142
TABLE 120 ASIA PACIFIC: HEMOSTATS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 142
9.4.1 CHINA 143
9.4.1.1 Growing number of hospitals and healthcare policy reforms are driving the growth of the hemostats market 143
TABLE 121 CHINA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 144
TABLE 122 CHINA: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 144
9.4.2 JAPAN 144
9.4.2.1 Strong healthcare system and rising geriatric population to support market growth in Japan 144
TABLE 123 JAPAN: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 145
TABLE 124 JAPAN: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 145
9.4.3 INDIA 146
9.4.3.1 Rising healthcare awareness and favorable government support to propel market growth in India 146
TABLE 125 INDIA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 147
TABLE 126 INDIA: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 147
9.4.4 AUSTRALIA 147
9.4.4.1 Rising prevalence of chronic diseases to drive market growth 147
TABLE 127 AUSTRALIA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 148
TABLE 128 AUSTRALIA: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 148
9.4.5 SOUTH KOREA 148
9.4.5.1 Growing number of cosmetic surgeries to drive the demand for hemostats in South Korea 148
TABLE 129 SURGICAL PROCEDURES IN SOUTH KOREA, 2019 149
TABLE 130 SOUTH KOREA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 149
TABLE 131 SOUTH KOREA: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 149
9.4.6 SINGAPORE 150
9.4.6.1 Government initiatives to promote the country’s healthcare services to support market growth 150
TABLE 132 SINGAPORE: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 150
TABLE 133 SINGAPORE: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 151
9.4.7 NEW ZEALAND 151
9.4.7.1 Increasing number of bariatric surgeries to propel market growth 151
TABLE 134 NEW ZEALAND: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 151
TABLE 135 NEW ZEALAND: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 152
9.4.8 INDONESIA 152
9.4.8.1 Indonesia offers lucrative growth opportunities for players in the hemostats market 152
TABLE 136 INDONESIA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 153
TABLE 137 INDONESIA: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 153
9.4.9 MALAYSIA 153
9.4.9.1 Low healthcare costs, modern medical technology, and highly qualified doctors to favor market growth in the country 153
TABLE 138 MALAYSIA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 154
TABLE 139 MALAYSIA: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 154
9.4.10 REST OF ASIA PACIFIC 154
TABLE 140 ROAPAC: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 155
TABLE 141 ROAPAC: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 155
9.5 LATIN AMERICA 155
TABLE 142 LATIN AMERICA: HEMOSTATS MARKET, BY COUNTRY,
2016–2019 (USD MILLION) 156
TABLE 143 LATIN AMERICA: HEMOSTATS MARKET, BY COUNTRY,
2020–2026 (USD MILLION) 156
TABLE 144 LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 156
TABLE 145 LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 157
TABLE 146 LATIN AMERICA: HEMOSTATS MARKET, BY FORMULATION,
2016–2019 (USD MILLION) 157
TABLE 147 LATIN AMERICA: HEMOSTATS MARKET, BY FORMULATION,
2020–2026 (USD MILLION) 157
TABLE 148 LATIN AMERICA: HEMOSTATS MARKET, BY APPLICATION,
2016–2019 (USD MILLION) 158
TABLE 149 LATIN AMERICA: HEMOSTATS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 158
9.5.1 BRAZIL 158
9.5.1.1 Brazil accounted for the largest share of the LATAM market in 2020 158
TABLE 150 BRAZIL: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 159
TABLE 151 BRAZIL: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 159
9.5.2 MEXICO 160
9.5.2.1 Low-cost surgeries are driving medical tourism in Mexico 160
TABLE 152 MEXICO: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION) 160
TABLE 153 MEXICO: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION) 161
9.5.3 REST OF LATIN AMERICA 161
TABLE 154 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY TYPE,
2016–2019 (USD MILLION) 161
TABLE 155 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY TYPE,
2020–2026 (USD MILLION) 162
9.6 MIDDLE EAST & AFRICA 162
9.6.1 MEA IS THE SMALLEST REGIONAL MARKET FOR HEMOSTATS 162
TABLE 156 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY TYPE,
2016–2019 (USD MILLION) 163
TABLE 157 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY TYPE,
2020–2026 (USD MILLION) 163
TABLE 158 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY FORMULATION,
2016–2019 (USD MILLION) 164
TABLE 159 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY FORMULATION,
2020–2026 (USD MILLION) 164
TABLE 160 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY APPLICATION,
2016–2019 (USD MILLION) 164
TABLE 161 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY APPLICATION,
2020–2026 (USD MILLION) 165
10 COMPETITIVE LANDSCAPE 166
10.1 OVERVIEW 166
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 166
TABLE 162 OVERVIEW OF STRATEGIES ADOPTED BY KEY HEMOSTAT PLAYERS 166
10.3 REVENUE ANALYSIS 168
FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN THE HEMOSTATS MARKET 168
10.4 MARKET SHARE ANALYSIS 168
FIGURE 35 HEMOSTATS MARKET SHARE ANALYSIS, 2020 169
TABLE 163 HEMOSTATS MARKET: DEGREE OF COMPETITION 169
10.5 COMPETITIVE LEADERSHIP MAPPING 170
FIGURE 36 HEMOSTATS MARKET: COMPETITIVE LEADERSHIP MAPPING (2020) 171
10.6 COMPETITIVE LEADERSHIP MAPPING FOR SMES/START-UPS 172
FIGURE 37 HEMOSTATS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR SMES & START-UPS (2020) 173
10.7 COMPANY FOOTPRINT 174
TABLE 164 COMPANY FOOTPRINT 174
TABLE 165 COMPANY TYPE FOOTPRINT 175
TABLE 166 COMPANY REGIONAL FOOTPRINT 177
10.8 COMPETITIVE SCENARIO 178
10.8.1 DEALS 178
TABLE 167 KEY DEALS, JANUARY 2018– JUNE 2021 178
10.8.2 PRODUCT LAUNCHES & APPROVALS 179
TABLE 168 KEY PRODUCT LAUNCHES & APPROVALS, JANUARY 2018– JUNE 2021 179
10.8.3 OTHER DEVELOPMENTS 180
TABLE 169 OTHER DEVELOPMENTS, JANUARY 2018– JUNE 2021 180
11 COMPANY PROFILES 181
11.1 KEY PLAYERS 181
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
11.1.1 BECTON, DICKINSON & COMPANY (C. R. BARD) 181
TABLE 170 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 181
FIGURE 38 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020) 182
11.1.2 BAXTER INTERNATIONAL, INC. 184
TABLE 171 BAXTER INTERNATIONAL: BUSINESS OVERVIEW 184
FIGURE 39 BAXTER INTERNATIONAL: COMPANY SNAPSHOT (2020) 185
11.1.3 TELEFLEX INCORPORATED 188
TABLE 172 TELEFLEX INCORPORATED: BUSINESS OVERVIEW 188
FIGURE 40 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2020) 189
11.1.4 B. BRAUN MELSUNGEN AG 191
TABLE 173 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW 191
FIGURE 41 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT (2020) 192
11.1.5 JOHNSON & JOHNSON (ETHICON, INC.) 194
TABLE 174 JOHNSON & JOHNSON: BUSINESS OVERVIEW 194
FIGURE 42 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2020) 195
11.1.6 MEDTRONIC PLC 197
TABLE 175 MEDTRONIC PLC: BUSINESS OVERVIEW 197
FIGURE 43 MEDTRONIC PLC: COMPANY SNAPSHOT (2020) 198
11.1.7 HEMOSTASIS, LLC 199
TABLE 176 HEMOSTASIS, LLC: BUSINESS OVERVIEW 199
11.1.8 PFIZER INC. 200
TABLE 177 PFIZER INC.: BUSINESS OVERVIEW 200
FIGURE 44 PFIZER INC.: COMPANY SNAPSHOT (2020) 201
11.1.9 STRYKER 202
TABLE 178 STRYKER CORPORATION: BUSINESS OVERVIEW 202
FIGURE 45 STRYKER: COMPANY SNAPSHOT (2020) 203
11.1.10 CRYOLIFE, INC. 205
TABLE 179 CRYOLIFE, INC.: BUSINESS OVERVIEW 205
FIGURE 46 CRYOLIFE, INC.: COMPANY SNAPSHOT (2020) 206
11.1.11 MARINE POLYMER TECHNOLOGIES 207
TABLE 180 MARINE POLYMER TECHNOLOGIES: BUSINESS OVERVIEW 207
11.1.12 GELITA MEDICAL GMBH 208
TABLE 181 GELITA MEDICAL GMBH: BUSINESS OVERVIEW 208
11.1.13 INTEGRA LIFESCIENCES HOLDINGS CORPORATION 210
TABLE 182 INTEGRA LIFESCIENCES HOLDINGS CORPORATION: BUSINESS OVERVIEW 210
FIGURE 47 INTEGRA LIFESCIENCES HOLDINGS CORPORATION: COMPANY SNAPSHOT (2020) 211
11.1.14 ADVANCED MEDICAL SOLUTIONS GROUP PLC 212
TABLE 183 ADVANCED MEDICAL SOLUTIONS GROUP PLC: BUSINESS OVERVIEW 212
FIGURE 48 ADVANCED MEDICAL SOLUTIONS GROUP PLC: COMPANY SNAPSHOT (2020) 213
11.1.15 BETATECH MEDICAL 215
TABLE 184 BETATECH MEDICAL: BUSINESS OVERVIEW 215
11.1.16 MERIL LIFE SCIENCES PVT. LTD. 216
TABLE 185 MERIL LIFE SCIENCES PVT. LTD.: BUSINESS OVERVIEW 216
11.1.17 SAMYANG HOLDINGS CORPORATION 217
TABLE 186 SAMYANG HOLDINGS CORPORATION: BUSINESS OVERVIEW 217
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
11.2 OTHER PLAYERS 218
11.2.1 BIOM’UP 218
11.2.2 BIOCER ENTWICKLUNGS-GMBH 218
11.2.3 UNILENE 219
11.2.4 KATSAN MEDICAL DEVICES 219
11.2.5 TRICOL BIOMEDICAL INC. 220
11.2.6 STARSIL HEMOSTAT 220
11.2.7 3-D MATRIX MEDICAL TECHNOLOGY 221
11.2.8 MEDTRADE PRODUCTS LIMITED 221
11.2.9 ALTAYLAR MEDICAL 222
12 APPENDIX 223
12.1 DISCUSSION GUIDE 223
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 227
12.3 AVAILABLE CUSTOMIZATIONS 229
12.4 RELATED REPORTS 229
12.5 AUTHOR DETAILS 230

Lateral Flow Assay Components Market by Type, Application Type (Clinical Testing (Infectious, Cardiac Marker Test) Veterinary, Food Safety), Technique...

Publisher:        MarketsandMarkets

# of Pages:        224

Rating: 

1 User License $4,950

Publication Date:  April, 2022

Price:       $4,950 / User License




1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.2.1 CATEGORY-WISE INCLUSIONS AND EXCLUSIONS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 33
1.3 MARKET SCOPE 34
1.3.1 MARKETS COVERED 34
FIGURE 1 LATERAL FLOW ASSAY COMPONENTS MARKET SEGMENTATION 34
1.3.2 YEARS CONSIDERED FOR THE STUDY 35
1.4 CURRENCY 35
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 35
1.5 STAKEHOLDERS 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH APPROACH 36
FIGURE 2 RESEARCH DESIGN 36
2.1.1 SECONDARY DATA 36
2.1.1.1 Key data from secondary sources 37
2.1.2 PRIMARY DATA 38
2.1.2.1 Primary sources 38
2.1.2.2 Key data from primary sources 39
2.1.2.3 Breakdown of primaries 39
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE):
BY COMPANY TYPE, DESIGNATION, AND REGION 39
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 40
2.2 MARKET SIZE ESTIMATION 40
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021) 41
FIGURE 6 SUPPLY-SIDE ANALYSIS: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 42
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 44
FIGURE 7 DATA TRIANGULATION METHODOLOGY 45
2.4 KEY INDUSTRY INSIGHTS 46
2.5 LIMITATIONS 46
2.5.1 METHODOLOGY-RELATED LIMITATIONS 46
2.6 RISK ASSESSMENT 47
2.7 ASSUMPTIONS FOR THE STUDY 47
 
3 EXECUTIVE SUMMARY 48
FIGURE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2022 VS. 2027 (USD MILLION) 48
FIGURE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2022 VS. 2027 (USD MILLION) 49
FIGURE 10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION) 50
FIGURE 11 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2022 VS. 2027 (USD MILLION) 51
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 52
4 PREMIUM INSIGHTS 53
4.1 LATERAL FLOW ASSAY COMPONENTS MARKET OVERVIEW 53
FIGURE 13 RISING NUMBER OF LOCAL MANUFACTURERS FOR COMPONENTS IS DRIVING THE GROWTH OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 53
4.2 REGIONAL MIX: LATERAL FLOW ASSAY COMPONENTS MARKET 54
FIGURE 14 APAC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 54
4.3 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE AND COUNTRY 55
FIGURE 15 MEMBRANES ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021 55
4.4 LATERAL FLOW ASSAY COMPONENTS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 56
4.5 LATERAL FLOW ASSAY COMPONENTS MARKET: DEVELOPED VS. DEVELOPING COUNTRIES 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS: IMPACT ANALYSIS 57
5.2.1 DRIVERS 58
5.2.1.1 Growing demand for lateral flow assay kits due
to the COVID-19 pandemic 58
5.2.1.2 Growing usage of home-based lateral flow assay devices 58
5.2.1.3 Growing demand for point-of-care testing 58
5.2.1.4 Increasing public-private investments to develop lateral flow assays 59
5.2.2 RESTRAINTS 59
5.2.2.1 Availability of alternative diagnostic technologies 59
5.2.3 OPPORTUNITIES 59
5.2.3.1 Evolving applications of lateral flow assays 59
5.2.4 CHALLENGES 60
5.2.4.1 Requirement of specialized storage and shipping facilities for membranes 60
5.3 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES (YC-YCC) IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
FIGURE 16 YC–YCC SHIFT IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 61
5.5 AVERAGE SELLING PRICE TREND 61
TABLE 2 AVERAGE SELLING PRICE OF LATERAL FLOW ASSAY COMPONENTS,
BY REGION, 2021 (USD) 61
5.6 ECOSYSTEM MARKET MAP 62
FIGURE 17 ECOSYSTEM: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 62
5.7 PATENT ANALYSIS 63
5.7.1 PATENT PUBLICATION TRENDS FOR LATERAL FLOW ASSAYS 63
FIGURE 18 GLOBAL PATENT PUBLICATION TRENDS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2016–2021 64
5.7.2 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 64
FIGURE 19 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR LATERAL FLOW ASSAYS COMPONENTS, 2016–2021 64
5.8 VALUE CHAIN ANALYSIS 65
5.9 REGULATORY LANDSCAPE 66
TABLE 3 REGULATORY STANDARDS/APPROVALS REQUIRED FOR LATERAL FLOW IMMUNOASSAY PRODUCTS, BY COUNTRY/REGION 66
5.9.1 NORTH AMERICA 66
5.9.2 EUROPE 67
5.9.3 ASIA PACIFIC 67
5.9.3.1 India 67
5.9.3.2 China 67
5.9.3.3 Japan 68
5.10 TECHNOLOGY ANALYSIS 69
5.10.1 KEY TECHNOLOGY: LATERAL FLOW ASSAYS 69
5.11 KEY CONFERENCES & EVENTS DURING 2021–2023 69
TABLE 4 LATERAL FLOW ASSAY COMPONENTS MARKET: DETAILED LIST OF CONFERENCES & EVENTS 69
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 70
5.12.1 KEY STAKEHOLDERS IN THE BUYING PROCESS 70
FIGURE 20 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
TABLE 5 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
5.12.2 BUYING CRITERIA 71
FIGURE 21 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
TABLE 6 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
5.13 PORTER’S FIVE FORCES ANALYSIS 72
TABLE 7 LATERAL FLOW ASSAY COMPONENTS MARKET:
PORTER’S FIVE FORCES ANALYSIS 72
5.13.1 THREAT FROM NEW ENTRANTS 72
5.13.2 THREAT FROM SUBSTITUTES 72
5.13.3 BARGAINING POWER OF BUYERS 73
5.13.4 BARGAINING POWER OF SUPPLIERS 73
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 73
6 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE 74
6.1 INTRODUCTION 75
TABLE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 75
6.2 MEMBRANES 75
TABLE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE,
2020–2027 (USD MILLION) 76
TABLE 10 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 76
6.2.1 NITROCELLULOSE MEMBRANES 77
6.2.1.1 Advantages of nitrocellulose membranes such as high protein-binding affinity and compatibility with a wide range of detection methods to drive market growth 77
TABLE 11 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 12 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (1 X 1 M SHEETS), BY REGION, 2020–2027 (IN THOUSANDS) 78
TABLE 13 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (20 MM X 1 M ROLLS), BY REGION, 2020–2027 (IN MILLIONS) 78
6.2.2 OTHER MEMBRANES 78
TABLE 14 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 79
6.3 PADS 80
TABLE 15 EXAMPLES OF DIFFERENT MATERIALS USED IN MANUFACTURING LATERAL FLOW ASSAY PADS 80
TABLE 16 LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 80
TABLE 17 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PADS, BY COUNTRY, 2020–2027 (USD MILLION) 81
6.3.1 SAMPLE PADS 81
6.3.1.1 Ability to promote even and controlled distribution of samples to drive market growth 81
TABLE 18 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SAMPLE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 82
6.3.2 CONJUGATE PADS 82
6.3.2.1 Conjugate pads play an important role in controlling the performance of lateral flow immunoassays 82
TABLE 19 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CONJUGATE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 83
6.3.3 ABSORBENT PADS 84
6.3.3.1 Absorbent pads prevent backflow—a key factor driving market growth 84
TABLE 20 LATERAL FLOW ASSAY COMPONENTS MARKET FOR ABSORBENT PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 84
6.4 OTHER COMPONENTS 84
TABLE 21 OTHER LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 85
7 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION 86
7.1 INTRODUCTION 87
TABLE 22 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 87
7.2 CLINICAL TESTING 87
TABLE 23 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 88
TABLE 24 LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 88
7.2.1 INFECTIOUS DISEASE TESTING 89
7.2.1.1 Rising demand for infectious disease testing in emerging markets to drive market growth 89
TABLE 25 LATERAL FLOW ASSAY COMPONENTS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 89
7.2.2 PREGNANCY & FERTILITY TESTING 90
7.2.2.1 Growing infertility levels due to changing lifestyles—a key factor driving market growth 90
TABLE 26 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PREGNANCY & FERTILITY TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 90
7.2.3 CARDIAC MARKER TESTING 91
7.2.3.1 Rising prevalence of cardiovascular diseases and growing government support to drive growth in this market segment 91
TABLE 27 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CARDIAC MARKER TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 92
7.2.4 CHOLESTEROL TESTING/LIPID PROFILING 92
7.2.4.1 Growing prevalence of obesity and CVD—
a key factor driving market growth 92
TABLE 28 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CHOLESTEROL TESTING/LIPID PROFILING, BY COUNTRY, 2020–2027 (USD MILLION) 93
7.2.5 DRUGS-OF-ABUSE TESTING 93
7.2.5.1 Technological advancements and a growing focus on workplace
drug testing are driving market growth 93
TABLE 29 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUGS-OF-ABUSE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 94
7.2.6 OTHER CLINICAL TESTING APPLICATIONS 94
TABLE 30 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER CLINICAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 95
7.3 VETERINARY DIAGNOSTICS 95
7.3.1 INFECTIOUS DISEASE OUTBREAKS (PARTICULARLY IN LARGE LIVESTOCK ANIMALS) TO DRIVE MARKET GROWTH 95
TABLE 31 LATERAL FLOW ASSAY COMPONENTS MARKET FOR VETERINARY DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 96
7.4 FOOD SAFETY & ENVIRONMENTAL TESTING 96
7.4.1 HIGH SENSITIVITY AND EASE OF USE ARE KEY FACTORS DRIVING THE DEMAND FOR LATERAL FLOW ASSAYS FOR FOOD SAFETY TESTING 96
TABLE 32 LATERAL FLOW ASSAY COMPONENTS MARKET FOR FOOD SAFETY & ENVIRONMENTAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
7.5 DRUG DEVELOPMENT & QUALITY TESTING 97
7.5.1 INCREASING FOCUS ON PRODUCT SAFETY AND QUALITY ASSURANCE TO DRIVE MARKET GROWTH IN THE COMING YEARS 97
TABLE 33 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUG DEVELOPMENT & QUALITY TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 98
8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE 99
8.1 INTRODUCTION 100
TABLE 34 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 100
8.2 SANDWICH ASSAYS 100
8.2.1 SANDWICH ASSAYS PROVIDE HIGHER LEVELS OF ASSAY SENSITIVITY AND SPECIFICITY THAN OTHER ASSAY TECHNIQUES—A KEY FACTOR DRIVING GROWTH IN THIS MARKET SEGMENT 100
TABLE 35 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SANDWICH ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 101
8.3 COMPETITIVE ASSAYS 101
8.3.1 REDUCED SELECTIVITY AND SENSITIVITY OF COMPETITIVE ASSAYS IN RELATION TO SANDWICH ASSAYS COULD HAMPER MARKET GROWTH 101
TABLE 36 LATERAL FLOW ASSAY COMPONENTS MARKET FOR COMPETITIVE ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 102
8.4 MULTIPLEX DETECTION ASSAYS 102
8.4.1 INCREASING ADOPTION OF MULTI-ANALYTE ASSAYS AMONG CLINICIANS TO DRIVE MARKET GROWTH 102
TABLE 37 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MULTIPLEX DETECTION ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION) 103
9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER 104
9.1 INTRODUCTION 105
TABLE 38 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 105
9.2 MEDICAL DEVICE MANUFACTURING COMPANIES 105
9.2.1 INCREASING USE OF POC TESTS IS DRIVING THE ADOPTION OF LATERAL FLOW ASSAY COMPONENTS AMONG MEDICAL DEVICE MANUFACTURING COMPANIES 105
TABLE 39 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE MANUFACTURING COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 106
9.3 MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES 106
9.3.1 GROWING INCLINATION TOWARD FAST AND EARLY DIAGNOSIS, ESPECIALLY IN RELATION TO THE CURRENT COVID-19 SCENARIO, WILL DRIVE MARKET GROWTH 106
TABLE 40 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES, BY COUNTRY,
2020–2027 (USD MILLION) 107
 
10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION 108
10.1 INTRODUCTION 109
FIGURE 22 CHINA TO REGISTER THE HIGHEST GROWTH IN THE LATERAL FLOW ASSAY COMPONENTS MARKET DURING THE FORECAST PERIOD 109
TABLE 41 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION,
2020–2027 (USD MILLION) 110
10.2 NORTH AMERICA 110
TABLE 42 NORTH AMERICA: MACROECONOMIC INDICATORS 110
FIGURE 23 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 111
TABLE 43 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 44 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 45 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 112
TABLE 46 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 113
TABLE 47 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 113
TABLE 48 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 114
TABLE 49 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 114
TABLE 50 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 115
10.2.1 US 115
10.2.1.1 Increasing R&D investments and venture capital funding from both large and small firms towards the development of lateral flow assay diagnostics to drive market growth in the US 115
TABLE 51 US: MACROECONOMIC INDICATORS 116
TABLE 52 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 116
TABLE 53 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 116
TABLE 54 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 117
TABLE 55 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 117
TABLE 56 US: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 57 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 118
TABLE 58 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 119
10.2.2 CANADA 119
10.2.2.1 Lateral flow assay components market in Canada is estimated to grow at a relatively lower rate than the US 119
TABLE 59 CANADA: MACROECONOMIC INDICATORS 119
TABLE 60 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 120
TABLE 61 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 120
TABLE 62 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 120
TABLE 63 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 64 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 121
TABLE 65 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 122
TABLE 66 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 122
10.3 EUROPE 122
TABLE 67 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 68 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 123
TABLE 69 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 123
TABLE 70 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 124
TABLE 71 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 124
TABLE 72 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 73 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 125
TABLE 74 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 126
10.3.1 GERMANY 126
10.3.1.1 Growing demand for POC testing to drive the lateral flow assay components market in Germany 126
TABLE 75 GERMANY: MACROECONOMIC INDICATORS 126
TABLE 76 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 127
TABLE 77 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 127
TABLE 78 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 127
TABLE 79 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 128
TABLE 80 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 81 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 129
TABLE 82 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 129
10.3.2 FRANCE 129
10.3.2.1 High prevalence of age-related chronic diseases and infectious diseases to drive market growth in France 129
TABLE 83 FRANCE: MACROECONOMIC INDICATORS 130
TABLE 84 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 130
TABLE 85 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 130
TABLE 86 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 131
TABLE 87 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 131
TABLE 88 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 89 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 132
TABLE 90 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 133
10.3.3 UK 133
10.3.3.1 Severe impact of the second wave of COVID-19 in the first half of 2021 resulted in higher adoption of rapid COVID tests in the UK 133
TABLE 91 UK: MACROECONOMIC INDICATORS 134
TABLE 92 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 134
TABLE 93 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 134
TABLE 94 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 135
TABLE 95 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 135
TABLE 96 UK: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 97 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 136
TABLE 98 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 137
10.3.4 ITALY 137
10.3.4.1 Growing initiatives towards decentralization of medical services in Italy are contributing to the market growth in the country 137
TABLE 99 ITALY: MACROECONOMIC INDICATORS 137
TABLE 100 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 138
TABLE 101 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 138
TABLE 102 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 138
TABLE 103 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 139
TABLE 104 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 105 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 140
TABLE 106 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 140
10.3.5 SPAIN 140
10.3.5.1 Increasing focus of international organizations and domestic players on the development of POC products in the country to drive market growth 140
TABLE 107 SPAIN: MACROECONOMIC INDICATORS 141
TABLE 108 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 141
TABLE 109 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 142
TABLE 110 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 142
TABLE 111 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 142
TABLE 112 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 113 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 143
TABLE 114 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 144
10.3.6 REST OF EUROPE 144
TABLE 115 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 144
TABLE 116 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 145
TABLE 117 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 145
TABLE 118 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 145
TABLE 119 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 120 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 146
TABLE 121 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 147
10.4 ASIA PACIFIC 147
FIGURE 24 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 148
TABLE 122 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 149
TABLE 123 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 149
TABLE 124 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 149
TABLE 125 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 150
TABLE 126 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 150
TABLE 127 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 128 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 151
TABLE 129 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 152
10.4.1 CHINA 152
10.4.1.1 Higher exports of lateral flow assay components during the COVID-19 pandemic to drive market growth in the country 152
TABLE 130 CHINA: MACROECONOMIC INDICATORS 153
TABLE 131 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 153
TABLE 132 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 153
TABLE 133 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 154
TABLE 134 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 154
TABLE 135 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 155
TABLE 136 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 155
TABLE 137 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 156
10.4.2 JAPAN 156
10.4.2.1 Increasing prevalence of age-related illnesses driving the growth of the lateral flow assay components market in Japan 156
TABLE 138 JAPAN: MACROECONOMIC INDICATORS 157
TABLE 139 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 157
TABLE 140 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 157
TABLE 141 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 158
TABLE 142 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 158
TABLE 143 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 144 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 159
TABLE 145 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 160
10.4.3 INDIA 160
10.4.3.1 Increasing number of local manufacturers, growing healthcare concerns, and rising income levels to propel the growth of this market 160
TABLE 146 INDIA: MACROECONOMIC INDICATORS 160
TABLE 147 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 161
TABLE 148 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 161
TABLE 149 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 161
TABLE 150 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 162
TABLE 151 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 162
TABLE 152 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 163
TABLE 153 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 163
10.4.4 AUSTRALIA 164
10.4.4.1 Increasing prevalence of infectious diseases, especially influenza, to drive the growth of the lateral flow assay components market in Australia 164
TABLE 154 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 164
TABLE 155 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 164
TABLE 156 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 165
TABLE 157 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 165
TABLE 158 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 166
TABLE 159 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 166
TABLE 160 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 167
10.4.5 REST OF ASIA PACIFIC 167
TABLE 161 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 167
TABLE 162 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 168
TABLE 163 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 168
TABLE 164 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 168
TABLE 165 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 169
TABLE 166 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 169
TABLE 167 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 170
 
10.5 LATIN AMERICA 170
10.5.1 HIGH DEMAND FOR HIV POC DEVICES IN THE REGION TO SUPPORT THE GROWTH OF THE MARKET 170
TABLE 168 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 169 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 171
TABLE 170 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD
TYPE, 2020–2027 (USD MILLION) 171
TABLE 171 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 172
TABLE 172 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 172
TABLE 173 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 173
TABLE 174 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 173
10.6 MIDDLE EAST & AFRICA 173
10.6.1 SIGNIFICANT SUPPORT FROM GOVERNMENTS AND GLOBAL FIRMS TOWARDS EXPANDING HEALTHCARE SERVICES DRIVES THE ADOPTION OF LATERAL FLOW ASSAYS 173
TABLE 175 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 174
TABLE 176 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 174
TABLE 177 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 175
TABLE 178 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 175
TABLE 179 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 175
TABLE 180 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 181 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 176
TABLE 182 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 177
11 COMPETITIVE LANDSCAPE 178
11.1 OVERVIEW 178
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 178
FIGURE 25 OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
11.3 REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
FIGURE 26 REVENUE SHARE ANALYSIS FOR THE KEY PLAYERS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 180
11.4 MARKET SHARE ANALYSIS 180
FIGURE 27 LATERAL FLOW ASSAY COMPONENTS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 181
TABLE 183 LATERAL FLOW ASSAY COMPONENTS MARKET: DEGREE OF COMPETITION 182
11.5 R&D ASSESSMENT OF KEY PLAYERS 183
FIGURE 28 R&D EXPENDITURE: MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2018 VS. 2020 183
11.6 GEOGRAPHIC REVENUE ASSESSMENT OF KEY PLAYERS 183
FIGURE 29 GEOGRAPHIC REVENUE ASSESSMENT: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 184
11.7 COMPANY EVALUATION QUADRANT 184
11.7.1 STARS 184
11.7.2 PERVASIVE PLAYERS 184
11.7.3 EMERGING LEADERS 185
11.7.4 PARTICIPANTS 185
FIGURE 30 LATERAL FLOW ASSAY COMPONENTS MARKET: COMPANY EVALUATION MATRIX, 2021 185
11.8 COMPETITIVE BENCHMARKING 186
11.8.1 OVERALL COMPANY FOOTPRINT 186
TABLE 184 OVERALL COMPANY FOOTPRINT (17 COMPANIES) 186
TABLE 185 COMPANY FOOTPRINT: BY TYPE (17 COMPANIES) 187
TABLE 186 COMPANY FOOTPRINT: BY REGION (17 COMPANIES) 188
11.9 COMPETITIVE SCENARIO 188
11.9.1 DEALS 189
TABLE 187 DEALS, JANUARY 2019–FEBRUARY 2022 189
11.9.2 OTHER DEVELOPMENTS 189
TABLE 188 OTHER DEVELOPMENTS, JANUARY 2019–FEBRUARY 2022 189
12 COMPANY PROFILES 190
12.1 KEY PLAYERS 190
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 DANAHER CORPORATION (PALL CORPORATION AND CYTIVA LIFE SCIENCE) 190
TABLE 189 DANAHER CORPORATION: BUSINESS OVERVIEW 190
FIGURE 31 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 191
12.1.2 SARTORIUS STEDIM BIOTECH 195
TABLE 190 SARTORIUS STEDIM BIOTECH: BUSINESS OVERVIEW 195
12.1.3 MERCK KGAA 199
TABLE 191 MERCK KGAA: BUSINESS OVERVIEW 199
FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2020) 200
12.1.4 AHLSTROM-MUNKSJÖ 204
TABLE 192 AHLSTROM-MUNKSJÖ: BUSINESS OVERVIEW 204
FIGURE 34 AHLSTROM-MUNKSJÖ: COMPANY SNAPSHOT (2020) 205
12.1.5 ADVANCED MICRODEVICES PVT. LTD. 208
TABLE 193 ADVANCED MICRODEVICES PVT. LTD.: BUSINESS OVERVIEW 208
12.1.6 DCN DIAGNOSTICS 210
TABLE 194 DCN DIAGNOSTICS: BUSINESS OVERVIEW 210
12.2 OTHER PLAYERS 211
12.2.1 FORTIS LIFE SCIENCES 211
TABLE 195 FORTIS LIFE SCIENCES: BUSINESS OVERVIEW 211
12.2.2 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD 212
TABLE 196 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD.:
BUSINESS OVERVIEW 212
12.2.3 AXIVA SICHEM BIOTECH 214
TABLE 197 AXIVA SICHEM BIOTECH: BUSINESS OVERVIEW 214
12.2.4 NUPORE FILTRATION SYSTEM 216
TABLE 198 NUPORE FILTRATION SYSTEM: BUSINESS OVERVIEW 216
12.2.5 BALLYA BIO 217
TABLE 199 BALLYA BIO: BUSINESS OVERVIEW 217
12.2.6 RUNBIO BIOTECH CO. LTD. 219
TABLE 200 RUNBIO BIOTECH CO. LTD.: BUSINESS OVERVIEW 219
12.2.7 NEENAH GESSNER 220
TABLE 201 NEENAH GESSNER: BUSINESS OVERVIEW 220
12.2.8 MAXIM BIOMEDICAL 221
TABLE 202 MAXIM BIOMEDICAL: BUSINESS OVERVIEW 221
12.2.9 CYTODIAGNOSTICS 222
TABLE 203 CYTODIAGNOSTICS: BUSINESS OVERVIEW 222
12.2.10 SENOVA GMBH 223
TABLE 204 SENOVA GMBH: BUSINESS OVERVIEW 223
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 224
13.1 DISCUSSION GUIDE 224
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 229
13.3 AVAILABLE CUSTOMIZATIONS 231
13.4 RELATED REPORTS 231
13.5 AUTHOR DETAILS 232

US Healthcare Environmental Services Market by Type (Janitorial/Core-Cleaning, Infection Control & Prevention, Front-of-house cleaning & Brand Experie...

Publisher:        MarketsandMarkets

# of Pages:        126

Rating: 

1 User License $4,950

Publication Date:  March, 2022

Price:       $4,950 / User License




1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION & SCOPE 15
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 16
1.2.2 MARKET SEGMENTATION 16
FIGURE 1 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET SEGMENTATION 16
1.2.3 YEARS CONSIDERED FOR THE STUDY 17
1.3 CURRENCY 17
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 17
1.4 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH APPROACH 19
FIGURE 2 RESEARCH DESIGN 19
2.1.1 SECONDARY RESEARCH 20
2.1.1.1 Key data from secondary sources 21
2.1.2 PRIMARY RESEARCH 21
FIGURE 3 PRIMARY SOURCES 22
2.1.2.1 Key data from primary sources 23
2.1.2.2 Insights from primary experts 23
2.1.2.3 Breakdown of primary interviews 24
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE (SUPPLY & DEMAND SIDE) AND DESIGNATION 24
2.2 MARKET SIZE ESTIMATION 25
FIGURE 5 MARKET SIZE APPROACH – REVENUE SHARE ANALYSIS 25
FIGURE 6 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 26
FIGURE 7 DEMAND-SIDE APPROACH 28
2.3 DATA TRIANGULATION 29
FIGURE 8 DATA TRIANGULATION METHODOLOGY 29
2.4 MARKET RANKING ANALYSIS 30
2.5 ASSUMPTIONS FOR THE STUDY 30
2.6 LIMITATIONS 31
2.6.1 METHODOLOGY-RELATED LIMITATIONS 31
2.6.2 SCOPE-RELATED LIMITATIONS 31
2.7 RISK ASSESSMENT 31
TABLE 2 RISK ASSESSMENT: US HEALTHCARE ENVIRONMENTAL SERVICES MARKET 31
 
3 EXECUTIVE SUMMARY 32
FIGURE 9 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 32
FIGURE 10 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET,
BY FACILITY TYPE, 2021 VS. 2026 (USD MILLION) 33
4 PREMIUM INSIGHTS 34
4.1 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET OVERVIEW 34
FIGURE 11 STRINGENT REGULATORY GUIDELINES ON INFECTION CONTROL & PREVENTION METHODS IS A KEY FACTOR DRIVING THE MARKET GROWTH 34
4.2 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE AND FACILITY TYPE 35
FIGURE 12 JANITORIAL/CORE-CLEANING SERVICES ACCOUNTED FOR THE LARGEST SHARE OF THE US HEALTHCARE ENVIRONMENTAL SERVICES
MARKET IN 2020 35
4.3 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE (2021–2026) 36
FIGURE 13 ACUTE CARE FACILITIES TO DOMINATE THE US HEALTHCARE ENVIRONMENTAL SERVICES MARKET DURING THE FORECAST PERIOD 36
5 MARKET OVERVIEW 37
5.1 INTRODUCTION 37
5.2 MARKET DYNAMICS 37
TABLE 3 MARKET DYNAMICS: HEALTHCARE ENVIRONMENTAL SERVICES MARKET 37
5.2.1 MARKET DRIVERS 38
5.2.1.1 Increasing prevalence of Hospital-acquired infections (HAIs) 38
5.2.1.2 Rising number of hospital admissions and surgeries 39
TABLE 4 US: PERCENTAGE INCREASE IN THE NUMBER OF SURGERIES PERFORMED 39
FIGURE 14 TOTAL ADMISSIONS IN ALL US HOSPITALS 40
FIGURE 15 TOTAL NUMBER OF HOSPITALS IN THE US 40
5.2.1.3 Shortage of in-house expertise and the rising need to reduce healthcare costs 41
5.2.1.4 Increasing outsourcing of cleaning services 41
5.2.2 MARKET RESTRAINTS 41
5.2.2.1 Healthcare facilities with an in-house EVS department 41
5.2.3 MARKET OPPORTUNITIES 42
5.2.3.1 Sustained acquisitions among strategic & financial buyers 42
TABLE 5 COMPANY ACQUISITIONS 42
5.2.4 MARKET CHALLENGES 42
5.2.4.1 Noncompliance with cleaning standards by EVS providers 42
5.3 INDUSTRY TRENDS 43
5.3.1 EMERGENCE OF NEW SURFACE DISINFECTANTS &
GREEN CLEANING PRODUCTS 43
5.3.2 DISINFECTION ROBOTS 44
5.3.3 MONITORING TOOLS FOR CLEANING QUALITY ASSESSMENT 44
5.4 TECHNOLOGY ANALYSIS 45
TABLE 6 TECHNOLOGY INNOVATION IN THE HEALTHCARE ENVIRONMENTAL
SERVICES MARKET 45
5.5 PATENT ANALYSIS 45
5.5.1 PATENT PUBLICATION TRENDS FOR HEALTHCARE ENVIRONMENTAL SERVICES 46
FIGURE 16 PATENT PUBLICATION TRENDS (JANUARY 2011–DECEMBER 2021) 46
5.5.2 JURISDICTION AND TOP APPLICANT ANALYSIS 47
FIGURE 17 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR HEALTHCARE ENVIRONMENTAL SERVICES PATENTS (JANUARY 2011–JANUARY 2022) 47
FIGURE 18 TOP APPLICANT COUNTRIES/REGIONS FOR HEALTHCARE ENVIRONMENTAL SERVICES PATENTS (JANUARY 2011–JANUARY 2022) 48
TABLE 7 LIST OF PATENTS/PATENT APPLICATIONS IN THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET, 2020–2021 48
5.6 IMPACT OF COVID-19 ON THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET 50
6 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE 51
6.1 INTRODUCTION 52
TABLE 8 US: HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 52
6.2 JANITORIAL SERVICES/CORE-CLEANING SERVICES 52
6.2.1 MANDATORY REGULAR CLEANING AND DISINFECTION OF HEALTHCARE FACILITIES TO DRIVE THE MARKET GROWTH 52
6.3 INFECTION PREVENTION & CONTROL SERVICES 53
TABLE 9 US: INFECTION PREVENTION & CONTROL SERVICE MARKET, BY TYPE,
2019–2026 (USD MILLION) 53
6.3.1 SPECIALIZED CLEANING SERVICES 53
6.3.1.1 Rising adoption of specialized services to reduce HAIs to drive the market growth 53
6.3.2 INFECTION PREVENTION & CONTROL CONSULTATION SERVICES 53
6.3.2.1 The provision of customized environmental services specific
to a healthcare facility ensures market demand 53
6.4 ENHANCED CLEANING TECHNOLOGY 54
6.4.1 RISING DEMAND FOR ADVANCED CLEANING SOLUTIONS TO DRIVE THE SEGMENT GROWTH 54
TABLE 10 EXAMPLES OF COMPANIES PROVIDING TECHNOLOGY & INNOVATION IN HEALTHCARE EVS 54
6.5 FRONT-OF-HOUSE CLEANING AND BRAND EXPERIENCE 56
6.5.1 RISING AWARENESS TOWARDS A CLEAN AND SAFE ENVIRONMENT DURING PANDEMICS TO SUSTAIN THE MARKET GROWTH 56
6.6 OTHER SERVICES 56
 
7 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE 57
7.1 INTRODUCTION 58
FIGURE 19 STATES WITH THE HIGHEST NUMBER OF COVID-19 ADMISSIONS
(FEBRUARY 2022) 58
TABLE 11 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE, 2019–2026 (USD MILLION) 59
7.2 ACUTE-CARE FACILITIES 59
TABLE 12 US: HEALTHCARE ENVIRONMENTAL SERVICES FOR ACUTE-CARE SETTINGS, BY TYPE 2019–2026 (USD MILLION) 59
7.2.1 ACUTE HOSPITALS 60
7.2.1.1 Increasing hospital admissions due to COVID-19 and the rising prevalence of HAIs propel the market growth 60
FIGURE 20 NUMBER OF HAIS REPORTED BY GENERAL ACUTE CARE HOSPITALS
IN THE US (2020) 60
FIGURE 21 HAIS REPORTED BY GENERAL ACUTE CARE HOSPITALS IN THE US (2020) 61
FIGURE 22 HAIS REPORTED BY CRITICAL ACCESS HOSPITALS (CAHS) IN THE US (2018) 61
7.2.2 MILITARY TREATMENT FACILITY 61
7.2.2.1 The increasing number of military ambulatory health services & funding to drive the market growth 61
FIGURE 23 MILITARY HEALTH SYSTEMS FACILITIES IN THE US (2021) 62
7.2.3 CHILDREN’S HOSPITALS 62
7.2.3.1 Rising cases of COVID-19 and infection-related mortality rates among children drive the market growth 62
7.2.4 AMBULATORY SURGERY CENTERS (ASCS) 63
7.2.4.1 ASCs save time and reduce the risk of HAIS; key factor driving the market growth 63
FIGURE 24 US SURGERY CASES BY SETTING: ASC VS. HOPD (2005-2020) 64
7.2.5 ACADEMIC MEDICAL CENTERS (AMCS) 64
7.2.5.1 Healthcare capacity expansion during COVID-19 drives the adoption of healthcare environmental services in AMCs 64
7.3 POST-ACUTE CARE FACILITIES 64
TABLE 13 US: HEALTHCARE ENVIRONMENTAL SERVICES FOR POST-ACUTE CARE SETTINGS, BY TYPE 2019–2026 (USD MILLION) 65
7.3.1 LONG-TERM ACUTE HOSPITALS (LTACH) 65
7.3.1.1 Increasing risk of infection due to prolonged hospital stays to drive the market growth 65
7.3.2 SKILLED NURSING FACILITIES (SNF) 66
7.3.2.1 Increasing admissions of elderly people in skilled nursing facilities to drive the market growth 66
7.3.3 OTHER POST-ACUTE CARE FACILITIES 66
7.4 NON-ACUTE CARE FACILITIES 67
TABLE 14 US: ENVIRONMENTAL SERVICES MARKET FOR NON-ACUTE CARE SETTINGS, BY TYPE, 2019–2026 (USD MILLION) 67
7.4.1 PHYSICIAN’S OFFICES AND CLINICS 67
7.4.1.1 High patient traffic leads to continuous cleaning & maintenance to drive the market growth 67
7.4.2 OTHER NON-ACUTE CARE FACILITIES 68
FIGURE 25 DISTRIBUTION OF INDUSTRY MEDICAL AND HEALTH R&D INVESTMENTS,
BY SEGMENT (2020) 68
8 COMPETITIVE LANDSCAPE 70
8.1 OVERVIEW 70
8.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 70
8.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET 71
8.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 72
8.4 MARKET RANKING ANALYSIS 73
FIGURE 27 US HEALTHCARE ENVIRONMENTAL SERVICE MARKET RANKING,
BY KEY PLAYER, 2020 73
8.5 COMPETITIVE BENCHMARKING 75
TABLE 15 FOOTPRINT OF COMPANIES IN THE HEALTHCARE ENVIRONMENTAL
SERVICES MARKET 75
TABLE 16 SERVICE FOOTPRINT OF COMPANIES 76
TABLE 17 END-USER FOOTPRINT OF COMPANIES 77
8.6 COMPETITIVE LEADERSHIP MAPPING 77
8.6.1 STARS 78
8.6.2 EMERGING LEADERS 78
8.6.3 PERVASIVE PLAYERS 78
8.6.4 PARTICIPANTS 78
FIGURE 28 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET:
COMPETITIVE LEADERSHIP MAPPING (2021) 79
8.7 COMPETITIVE SCENARIO 80
8.7.1 SERVICE APPROVALS/ENHANCEMENTS 80
8.7.2 DEALS 81
TABLE 19 DEALS, 2018–2022 81
8.7.3 OTHER DEVELOPMENTS 82
9 COMPANY PROFILES 83
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
9.1 SODEXO GLOBAL 83
TABLE 21 SODEXO GLOBAL: BUSINESS OVERVIEW 83
FIGURE 29 SODEXO GLOBAL: COMPANY SNAPSHOT (2021) 84
9.2 COMPASS GROUP (CROTHALL HEALTHCARE (US)) 87
TABLE 22 COMPASS GROUP: BUSINESS OVERVIEW 87
FIGURE 30 COMPASS GROUP: COMPANY SNAPSHOT (2021) 88
 
9.3 ARAMARK CORPORATION 90
TABLE 23 ARAMARK CORPORATION: BUSINESS OVERVIEW 90
FIGURE 31 ARAMARK CORPORATION: COMPANY SNAPSHOT (2021) 91
9.4 HOSPITAL HOUSEKEEPING SYSTEMS (HHS) (US) 94
TABLE 24 HOSPITAL HOUSEKEEPING SYSTEMS (HHS): BUSINESS OVERVIEW 94
9.5 HEALTHCARE SERVICES GROUP, INC. 97
TABLE 25 HEALTHCARE SERVICES GROUP, INC.: BUSINESS OVERVIEW 97
FIGURE 32 HEALTHCARE SERVICES GROUP: COMPANY SNAPSHOT (2020) 98
9.6 ABM INDUSTRIES INCORPORATED 100
TABLE 26 ABM INDUSTRIES INCORPORATED: BUSINESS OVERVIEW 100
FIGURE 33 ABM INDUSTRIES INCORPORATED: COMPANY SNAPSHOT (2020) 101
9.7 OCTOCLEAN 103
TABLE 27 OCTOCLEAN: BUSINESS OVERVIEW 103
9.8 SERVICEMASTER CLEAN (SERVICEMASTER TBS) 105
TABLE 28 SERVICEMASTER CLEAN.: BUSINESS OVERVIEW 105
9.9 CORVUS JANITORIAL SYSTEMS 107
TABLE 29 CORVUS JANITORIAL SYSTEMS: BUSINESS OVERVIEW 107
9.10 BRAVO! BUILDING SERVICES 109
TABLE 30 BRAVO! BUILDING SERVICES: BUSINESS OVERVIEW 109
9.11 POWERLINK ENVIRONMENTAL SERVICES, LLC 111
TABLE 31 POWERLINK ENVIRONMENTAL SERVICES, LLC: BUSINESS OVERVIEW 111
9.12 JANI-KING INTERNATIONAL, INC. 112
TABLE 32 JANI- KING INTERNATIONAL, INC: BUSINESS OVERVIEW 112
9.13 AVI FOOD SYSTEMS(US) 114
TABLE 33 AVI FOOD SYTEMS, INC.: BUSINESS OVERVIEW 114
9.14 SERVICON 115
TABLE 34 SERVICON: BUSINESS OVERVIEW 115
9.15 XANITOS, INC. 117
TABLE 35 XANITOS, INC.: BUSINESS OVERVIEW 117
9.16 STATHAKIS 119
TABLE 36 STATHAKIS: BUSINESS OVERVIEW 119
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
10 APPENDIX 120
10.1 INSIGHTS FROM INDUSTRY EXPERTS 120
10.2 DISCUSSION GUIDE 121
10.3 KNOWLEDGESTORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL 124
10.4 AVAILABLE CUSTOMIZATIONS 126
10.5 RELATED REPORTS 126
10.6 AUTHOR DETAILS 127